TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.08
+0.00%Margins
Gross margin
89.4%
EBITDA margin
65.6%
EBIT margin
4.5%
Net margin
51.6%
FCF margin
49.7%
18.6%
Return on equity
11.5%
Return on assets
1.4%
Return on invested capital
0.22x
Asset turnover
$51.8M
Cash from operations
$7.47
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026